PMID- 28293968
OWN - NLM
STAT- MEDLINE
DCOM- 20170608
LR  - 20170608
IS  - 1751-2441 (Electronic)
IS  - 1751-2433 (Linking)
VI  - 10
IP  - 5
DP  - 2017 May
TI  - Clinical pharmacology of tocilizumab for the treatment of polyarticular-course 
      juvenile idiopathic arthritis.
PG  - 471-482
LID - 10.1080/17512433.2017.1300058 [doi]
AB  - The efficacy and safety of tocilizumab (TCZ), a humanized anti-interleukin-6 
      receptor (IL-6R) monoclonal antibody, in patients with polyarticular-course 
      juvenile idiopathic arthritis (pJIA) were demonstrated in clinical trials. Area 
      covered: A literature search was undertaken in the public domain from 1995 to 
      2016. Data included in the regulatory submission leading to approval of TCZ for 
      the treatment of pJIA in the European Union, United States, and Japan were also 
      presented. TCZ 10 mg/kg in patients weighing <30 kg provided pharmacokinetic 
      exposure comparable to that of TCZ 8 mg/kg for patients >/=30 kg. Pharmacodynamic 
      (C-reactive protein, erythrocyte sedimentation rate, IL-6, and soluble IL-6R) and 
      efficacy outcomes were comparable between TCZ 10 mg/kg in patients <30 kg and TCZ 
      8 mg/kg in patients >/=30 kg. Proportions of patients achieving JIA ACR 30/50/70/90 
      responses at week 16 increased with higher exposure (mean+/-SD C(min) from quartile 
      1 to quartile 4: 0.02 +/- 0.047, 0.98 +/- 0.707, 5.00 +/- 1.73, and 16.54 +/- 7.74 microg/mL; 
      n = 42). The adverse event rate did not increase with increased exposure. Data 
      support weight-based dosing regimens. Expert commentary: Biologics have improved 
      outcomes for patients with pJIA with inadequate response to conventional therapy. 
      TCZ will likely become an increasingly important treatment option for the 
      management of pJIA.
FAU - Zhang, Xiaoping
AU  - Zhang X
AD  - a Department of Clinical Pharmacology , Hoffmann La-Roche Inc. , Nutley , NJ , 
      USA.
FAU - Chen, Ya-Chi
AU  - Chen YC
AD  - b Department of Clinical Pharmacology , Hoffmann-La Roche Inc. , New York , NY , 
      USA.
FAU - Terao, Kimio
AU  - Terao K
AD  - c Department of Clinical Pharmacology , Chugai Pharmaceutical Co., Ltd. , Tokyo , 
      Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170315
PL  - England
TA  - Expert Rev Clin Pharmacol
JT  - Expert review of clinical pharmacology
JID - 101278296
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Receptors, Interleukin-6)
RN  - I031V2H011 (tocilizumab)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal, Humanized/*administration & dosage/adverse 
      effects/pharmacology
MH  - Antirheumatic Agents/*administration & dosage/adverse effects/pharmacology
MH  - Arthritis, Juvenile/*drug therapy/immunology/physiopathology
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Receptors, Interleukin-6/immunology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - C-reactive protein
OT  - Clinical pharmacology
OT  - exposure-response relationship
OT  - interleukin-6
OT  - interleukin-6 receptor
OT  - pharmacokinetics
OT  - polyarticular-course juvenile idiopathic arthritis
OT  - tocilizumab
EDAT- 2017/03/16 06:00
MHDA- 2017/06/09 06:00
CRDT- 2017/03/16 06:00
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2017/06/09 06:00 [medline]
PHST- 2017/03/16 06:00 [entrez]
AID - 10.1080/17512433.2017.1300058 [doi]
PST - ppublish
SO  - Expert Rev Clin Pharmacol. 2017 May;10(5):471-482. doi: 
      10.1080/17512433.2017.1300058. Epub 2017 Mar 15.